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In the original publication, corresponding
author e-mail address and Fig. 2 were published
incorrectly. The correct e-mail address and the
revised Fig. 2 are given here.
The corresponding author’s e-mail address
should read as fgomezp@saludcastillayleon.es.
The incorrect statement in Fig. 2 ‘‘BP\140/
80 mmHg, aged older than 65 years or hemo-
dynamically unstable*?’’ should read as
‘‘BP\140/80 mmHg, aged older than 65 years or
hemodynamically unstable**?’’
The incorrect statement in Fig. 2 ‘‘Reintroduce
treatment according to clinical situation**?’’
should read as ‘‘Reintroduce treatment accord-
ing to clinical situation***?’’
The online version of the original article can be found
under doi:10.1007/s13300-017-0277-0.
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Fig. 2 Proposed algorithm for adjusting antidiabetic
agents (a) and diuretic/antihypertensive therapy
(b) when initiating SGLT2 inhibitors in patients with
type 2 diabetes. DPP4i DPP4 inhibitors, GI gastrointesti-
nal, GLP1ra GLP-1 receptor agonists, SU sulfonylureas,
SMBG self-monitoring of blood glucose, BP blood
pressure. *Avoid insulin withdrawal to minimize the risk
of euglycemic diabetic ketoacidosis. **Hemodynamically
unstable defined as atrial fibrillation, orthostatic hypoten-
sion or blood pressure lability, prior syncope, etc. ***Clin-
ical situation defined by congestive heart failure, edema,
renal function
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